2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit is organized by Hanson Wade and will be held from Sep 10 - 12, 2019 at Aloft Boston Seaport District, Boston, Massachusetts, United States of America.

Description:
Following the success of the first iCDP summit last year, we are returning this September to provide the primary industry platform for the advancement of cannabinoid-derived pharmaceuticals. When this summit takes place it will have been just over a year since GW Pharmaceutical's created the first FDA approved drug containing a cannabinoid API, and several contenders are hot on their heels. However, there are many challenges still obstructing the development of this generation of cannabinoid pharmaceuticals.

Join your peers at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit to solve your challenges in this fast growing field, and to maximise the potential of the next-generation of cannabinoid pharmaceuticals.

Through an array of case studies, panels, interactive workshops and a poster session, the International Cannabinoid Derived Pharmaceuticals Summit offers practical insight that is aimed to help biotechs at all R&D stages make more informed decisions, to further advance their pipelines and the field of cannabinoid pharmaceuticals.

Workshop Details:
Workshop A
Tue, September 10, 2019
09:00 – 12:00
Conducting Effective Preclinical Studies Using Cannabinoids, in the Context of Cancer
Description:
The goal of the workshop will be to give an overview of the current state of preclinical research on cannabinoid-based therapeutic approaches, with emphasis on the effects of cannabinoids in animal models of pain and CNS injury/disease.

Topics:
Specific topics to be covered will include:
• The types of cannabinoid-based therapies being tested
• The appropriateness of the preclinical models used across laboratories
• Potential issues surrounding disconnects between preclinical and clinical results
The workshop will be comprised of a lecture-based format as well as smaller group brainstorming sessions

Workshop B
Tue, September 10, 2019
13:00 – 16:00
Cannabinoid Formulation & Methods of Administration
Description:
Establishing an effective dosing and dose administration strategy is an integral part of the early development of your cannabinoid drug. It ensures both the effectiveness and the safety of it to your patients. This workshop is an expansion of the highly popular formulation workshop we featured at CDP 2018. This workshop will take aim at the critical issues surrounding the preclinical formulation and assessment of cannabinoids.

At this workshop, attendees will discuss:
• Enhancing the bioavailability of cannabinoids
• Single vs. combinations of cannabinoids
• Current understanding of drug-drug interactions
• Avoiding the issues associated with the first pass effect

Speakers: Guy Chamberland, Chief Executive Officer, Tetra Biopharma, Dennis Ahern, Vice President, Global Regulatory Affairs, Greenwich Biosciences, Mara Gordon, Founder & Director, Zelda Therapeutics, Brian Murphy, Chief Executive Officer, Emerald Biopharma, Sara Ward, Researcher, Oncology, Temple University, Ethan Russo, Professor, International Cannabis and Cannabinoids Institute, Andrea Small-Howard, Chief Science Officer, GB Sciences, Robert Walsh, Chief of Regulatory Affairs Branch Division of Therapeutics & Medical Consequences of Drug Abuse,NIDA, Sagnik Bhattacharyya, Reader of Translational Neuroscience & Psychiatry, King's College London